

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,595,154
APPLICATION NO. : 10/517,905
ISSUE DATE : September 29, 2009
INVENTORS : Heinrich *et al.*

Page 1 of 3

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Section 56 "Reference Cited", under "Other Publications":

Page 2, Column 1, Debiec-Rychter *et al.*, "studies" should be --studies--.

Page 2, Column 1, Gari *et al.*, "proto-ocogene" should be --proto-oncogene--.

Page 2, Column 1, Heinrich *et al.* (first entry), "alternations" should be --alterations--.

Page 2, Column 2, Madani *et al.*, "28-21" should be --18-21--.

Page 2, Column 2, GleevecTM..., "gove/" should be --gov/--.

In the Specification:

Column 2, Line 2, "1052" should be --344--.

Column 3, Lines 10-11, "system Sample" should be --system. Sample--.

Column 3, Line 18, "18174R" should be --181874R--.

Column 3, Line 52, "would identifiable" should be --would be identifiable--.

Column 3, Line 58, "DGFRA" should be --PDGFRA--.

Column 3, Line 61, "phosphor-tyrosine" should be --phospho-tyrosine--.

Column 5, Line 16, "protein SEQ ID NO: 25" is missing a return, and should be
--protein.

SEQ ID NO: 25-- (new paragraph).

Column 6, Line 48, "to" should be --two--.

Column 6, Line 54, "target The" should be --target. The--.

Column 7, Line 27, "ingredient The" should be --ingredient. The--.

Column 9, Line 11, "tract Generally" should be --tract. Generally--.

Column 9, Line 55, "or increased or increased" should be --or increased or decreased--.

Column 10, Line 53, "sequences." should be --sequence--.

Column 11, Line 20, "term Thus" should be --term. Thus--.

Column 11, Line 48, "art Various" should be --art. Various--.

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland Oregon, 97204

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,595,154
APPLICATION NO. : 10/517,905
ISSUE DATE : September 29, 2009
INVENTORS : Heinrich *et al.*

Page 2 of 3

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- Column 12, Line 12, “Tm” should be --T_m--.
- Column 13, Line 2, “F(ab')₂” should be -- F(ab')₂--.
- Column 13, Line 18, “effectively oligonucleotide” should be --effective oligonucleotide(s)--.
- Column 14, Line 15, “thereof comprising including” should --thereof including--.
- Column 14, Line 46, “agent In” should be --agent. In--.
- Column 14, Line 55, “fragments” should be --fragment--.
- Column 16, Line 7, “shown in shown in” should be --shown in--.
- Column 17, Line 60, “& and” should be --&--.
- Column 18, Line 8, “immunaffinity” should be --immunoaffinity--.
- Column 18, Line 27, “imatimb” should be --imatinib--.
- Column 18, Line 38, “TK1” should be --TKI--.
- Column 19, Line 24, “3140” should be --31-40--.
- Column 19, Line 31, “TK1” should be --TKI--.
- Column 20, Line 1, “CSF-LR” should be --CSF-1R--.
- Column 21, Lines 41-42, “neoplasia In” should be --neoplasia. In--.
- Column 25, Line 9, “CSF1-R” should be --CSF-1R--.
- Column 25, Line 39, “aprotinin 10 μg” should be --aprotinin, 10 μg--.
- Column 26, Line 66, “181874R The” should be --181874R. The--.
- Column 29, Line 8, “PDGRA” should be --PDGFRA--.
- Column 31, Lines 35-36, “Nildforov” should be --Nikiforov--.
- Column 34, Line 30, “1998.” should be --1998).--.
- Column 39, Line 29, “adjuvant Also” should be --adjuvant. Also--.
- Column 40, Line 13, “ant-PDGFR” should be --anti-PDGFRA--.
- Column 40, Line 47, “SE ID NO: 10 positions” should be --SEQ ID NO: 10, positions--.
- Column 45, Line 66, “sequence the” should be --sequence of the --.

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland Oregon, 97204

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,595,154
APPLICATION NO. : 10/517,905
ISSUE DATE : September 29, 2009
INVENTORS : Heinrich *et al.*

Page 3 of 3

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 46, Line 63, "PDGR-A" should be --PDGFRA--.

Column 47, Line 29, "E1561" should be --ER561--.

Column 49, Line 34, "(86:4603-4611" should be --(*Blood* , 86:4603-4611--.

Column 50, Line 1, "determine" should be --determined--.

Column 51, Line 21, "Thr202Thr204" should be --Thr202/Thr204--.

Column 51, Line 24, "Y701, (Zymed" should be --Y701 (Zymed--.

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland Oregon, 97204